Alicaforsen
As of the edition of 20 October 2026, Alicaforsen is an oligonucleotide: went quiet in 2018; acts on ICAM1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2018
- Kind
- Oligonucleotide
- Registered trials
- 6, 0 stopped early
- Disease areas
- Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Alicaforsen.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ICAM1 | Intercellular adhesion molecule 1 | P05362 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 2 | 2 | 0 | 0 |
| Phase 3 | 3 | 3 | 0 | 0 |
| All trials | 6 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Akcea Therapeutics | Lead sponsor of trials | 2001 to now |
| Atlantic Therapeutics | Lead sponsor of trials | 2015 to now |